Do Not Discontinue Sertraline in This Patient
I strongly recommend against discontinuing sertraline in this patient with severe OCD and bipolar II disorder. The patient's desire to stop the medication does not align with evidence-based treatment principles for severe OCD, and discontinuation would likely result in significant worsening of her obsessive-compulsive symptoms with substantial impact on quality of life.
Why Sertraline Should Be Continued
SSRIs Are First-Line Treatment for Severe OCD
Sertraline is a first-line pharmacological treatment for OCD based on evidence of efficacy, tolerability, and safety 1. For severe OCD specifically, the recommended maintenance duration is a minimum of 12-24 months after achieving remission, but longer treatment is often necessary due to high relapse risk after discontinuation 1. This patient has severe OCD that is currently symptomatic despite treatment—she has not achieved remission and therefore does not meet criteria for safe discontinuation.
Evidence Shows High Relapse Risk
The literature clearly demonstrates that discontinuing SSRIs in OCD leads to symptom relapse 1. Given that this patient's OCD is described as "severe" and she continues to have "severe OCD symptoms," stopping her SSRI would predictably worsen her condition and quality of life.
Current Dose May Be Subtherapeutic
The patient is only on sertraline 100 mg daily. Higher doses of SSRIs are routinely used for OCD than for depression or other anxiety disorders, with doses of 50-200 mg/day demonstrating efficacy 2, 3, 4. Studies show that 200 mg/day of sertraline is safe and effective for OCD 3, 5, 4. Before considering discontinuation, the dose should be optimized to 150-200 mg/day to achieve adequate therapeutic effect.
Alternative Management Strategy
Step 1: Optimize Sertraline Dosing
- Increase sertraline to 150-200 mg/day over 2-4 weeks 2
- Allow 8-12 weeks at the higher dose to assess full therapeutic response 1
- Monitor for improvement in OCD symptoms using standardized measures
Step 2: Consider Augmentation if Inadequate Response
If sertraline optimization fails, evidence-based augmentation strategies include 1:
- Adding CBT with exposure and response prevention (ERP) - this has the largest effect size and is superior to medication augmentation alone 1
- Antipsychotic augmentation (aripiprazole or risperidone) - though this adds to her existing quetiapine
- Glutamatergic agents (N-acetylcysteine, memantine) as alternatives
Step 3: Address Bipolar Considerations
The patient has bipolar II disorder, which requires careful consideration:
- Sertraline is not approved for bipolar depression and can theoretically precipitate mood episodes 2
- However, she is on quetiapine 100 mg, which provides mood stabilization
- If mood symptoms are the concern, optimize quetiapine dosing (300-600 mg/day for bipolar depression) rather than stopping the SSRI 6
If Patient Absolutely Insists on Discontinuation
Only if the patient refuses all alternatives and demands discontinuation despite counseling:
Tapering Protocol
- Taper sertraline by 25% every 1-2 weeks (this is the benzodiazepine taper schedule from 7, 8, but applies to gradual medication discontinuation generally)
- More conservatively: reduce by 25 mg every 2-4 weeks given the 24-hour half-life 2
- Monitor closely for:
- Worsening OCD symptoms (obsessions, compulsions, functional impairment)
- SSRI discontinuation syndrome (dizziness, paresthesias, anxiety, irritability)
- Mood destabilization
Critical Monitoring
- Do not abruptly discontinue - gradual tapering is essential 2
- Expect return of OCD symptoms within weeks to months after the last dose 9
- Have a plan to reinitiate treatment when symptoms worsen
Address the Underlying Issue
Explore why the patient wants to stop sertraline:
- Side effects? (sexual dysfunction, GI symptoms) - these can be managed
- Lack of perceived benefit? - likely undertreated at current dose
- Medication burden? - consider that OCD requires long-term treatment
- Cost or access issues? - address these barriers directly
Critical Pitfall to Avoid
The most common error would be to simply honor the patient's request without addressing the clinical reality: discontinuing an SSRI in a patient with severe, active OCD will result in predictable worsening of symptoms and deterioration in quality of life. This is not patient-centered care—it is abandoning evidence-based treatment. The appropriate response is therapeutic education, dose optimization, and augmentation strategies, not discontinuation.